InterCure Completes Botanico Acquisition, Initiates Strategic Review for U.S. Medical Cannabis Market Entry
INCR sits 35% above its 52-week low of $0.68 on light trading volume (0.4× avg).
Summary
InterCure completed the initial closing of its Botanico acquisition, issuing approximately 2.47 million ordinary shares. This deal, also noted in a 6-K filed today, provides exclusive access to U.S. cannabis genetics, premium brands, and AI-driven technologies, significantly expanding the company's international platform. Concurrently, InterCure initiated a strategic review of U.S. medical cannabis opportunities, capitalizing on the recent federal rescheduling. This move positions the company for potential entry into a major new market, representing a significant growth opportunity.
At the time of this announcement, INCR was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50M. The 52-week trading range was $0.68 to $1.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.